COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE PHARMACOLOGICAL TREATMENTS OF ACROMEGALY IN SPAIN

被引：3
|
作者：
Peral, C. [1 ]
Cordido, F. [2 ]
Gimeno, V [3 ]
Sanchez-Cenizo, L. [1 ]
Mir, N. [1 ]
Parrondo, J. [4 ]
机构：
[1] Pfizer SLU, Alcobendas, Madrid, Spain
[2] Hosp A Coruna, La Coruna, Spain
[3] Hosp Miguel Servet, Zaragoza, Spain
[4] JParrondo Hlth, Madrid, Spain
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.901
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY75
引用
收藏
页码：A557 / A558
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia
    Whalen, John
    Stillman, Ipek
    Ambavane, Apoorva
    Felber, Eugene
    Makenbaeva, Dinara
    Bolinder, Bjorn
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (05) : 445 - 461
  • [32] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB AS A SECOND-LINE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA IN THE UNITED STATES
    Chen, N. C.
    McQueen, R.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [33] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    [J]. FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [34] COST-EFFECTIVENESS OF RITUXIMAB AS SECOND-LINE BIOLOGICAL TREATMENT COMPARED TO REGISTRY DATA
    Kobelt, G.
    Lindgren, P.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A548 - A548
  • [35] Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia
    Goshua, George
    Sinha, Pranay
    Pischel, Lauren
    Lee, Alfred Ian
    Cuker, Adam
    [J]. BLOOD, 2021, 138
  • [36] Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis
    Dowdy, D. W.
    van't Hoog, A.
    Shah, M.
    Cobelens, F.
    [J]. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (06) : 647 - 654
  • [37] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    [J]. VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [38] Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.
    Lauren, Brianna
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Ostvar, Sassan
    Laszkowska, Monika
    Chu, Jacqueline N.
    Manji, Gulam Abbas
    Neugut, Alfred I.
    Hur, Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    [J]. PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [40] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    [J]. PharmacoEconomics, 2004, 22 : 581 - 589
12345